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A B S T R A C T 
Heparin, despite its significant side-effects, is the 
most commonly used anticoagulant for continuous 
renal replacement therapy in critical care setting. 
In recent years, citrate has gained much popularity 
by improving continuous renal replacement therapy 
circuit survival and decreasing blood transfusion 
requirements. However, its complex metabolic 
consequences warrant modification in the design 
of the citrate-based continuous renal replacement 
therapy protocol. With thorough understanding 
of the therapeutic mechanism of citrate, a simple 
and practicable protocol can be devised. Citrate-
based continuous renal replacement therapy can 
Risks and benefits of citrate anticoagulation for 
continuous renal replacement therapy
Introduction
Continuous renal replacement therapy (CRRT) is 
commonly used for the management of acute kidney 
injury in the intensive care unit (ICU) worldwide. 
Anticoagulation is necessary to prevent clotting of 
the extracorporeal circuit. Unfractionated heparin 
has the advantages of acceptable circuit life, low cost, 
easy monitoring and simple reversal, and hence, 
remains a popular choice.1,2 However, critically ill 
patients have various bleeding risks that may contra-
indicate the use of heparin. The contra-indications 
may include recent surgical procedures, multiple 
trauma, thrombocytopenia, and coagulation 
defects.3 Moreover, binding of heparin to endothelial 
antithrombin inhibits its anti-inflammatory actions 
and prevents local prostacyclin formation that, 
in turn, jeopardises micro-circulation.4,5 Hence, 
heparin use may be disadvantageous in patients with 
Gram-negative sepsis.4 Although implementation 
of an anticoagulation-free regimen is a safer 
alternative, circuit clotting occurs frequently, which 
not only increases treatment cost and downtime, but 
also increases the need of blood transfusion and the 
nursing workload. Among the various alternative 
anticoagulants like low-molecular-weight heparin, 
serine proteinase inhibitor nafamostat, prostacyclin, 
hirudin and direct thrombin inhibitor, citrate 
has gained popularity in recent years. This paper 
provides a general review on citrate use in CRRT and 
focuses on studies published in the past decade.
Mechanism of action
Citrate just mixes with the blood before it enters 
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the CRRT circuit as illustrated in the commonly 
used citrate-based CRRT regimens (Figures 1 to 
3). Citrate chelates the ionised calcium, which 
is essential for the normal coagulation cascade 
and results in inhibition of thrombin generation. 
An extracorporeal, post-filter, ionised calcium 
concentration of 0.25 to 0.35 mmol/L is effective to 
achieve the anticoagulation effect. The majority of 
citrate is removed by either filtration or dialysis with 
a sieving coefficient of one in both processes.6 The 
removal fraction varies from 20% to 80%, depending 
on the blood flow rate, effluent flow rate, and CRRT 
modality.7,8 The remaining calcium-citrate product 
enters the systemic circulation and is metabolised 
in the liver, muscles, and kidneys to produce three 
molecules of bicarbonate for every molecule of 
citrate. Replacement infusion of calcium is common-
ly given to compensate the extracorporeal loss and 
to normalise a patient’s systemic calcium level.8,9 The 
relative contra-indications for citrate-based CRRT 
include liver failure with or without cirrhosis, severe 
hypoxaemia, and after massive blood transfusion. 
Circuit survival
Factors affecting the circuit life include a patient’s 
clinical condition and coagulation status, the position 
and patency of the vascular access, the choice of 
anticoagulant, modality of CRRT, and filtration 
fraction.10,11 Most of the published randomised 
controlled trials (RCTs) indicate improved circuit 
survival with citrate versus heparin (Table 112-17).
Three meta-analyses have been published recently 
that summarise this issue.18-20 While Liao et al20 
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be safely and widely used in the clinical setting with 
appropriate clinical staff training.
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枸櫞酸抗凝作連續性腎臟替代治療的風險及效益
沈海平、殷榮華、陳德茂
肝素是連續性腎臟替代治療（CRRT）中最常用的抗凝血劑，然而與
其相關的副作用甚為顯著。枸櫞酸抗凝可以改善CRRT使用壽命及降
低輸血需求，因此枸櫞酸近年來逐漸普及。設計枸櫞酸CRRT方案時
要多加注意其複雜的代謝後果。通過深入了解其治療機制，設計簡單
可行的CRRT方案及適當培訓臨床人員，枸櫞酸抗凝可安全及被廣泛
應用。
only focused on RCTs that compare unfractionated 
heparin with citrate, Zhang and Hongying18 and Wu 
et al19 also included studies on low-molecular-weight 
heparin and regional heparin. They concluded that 
circuit life with citrate was comparable19,20 or better 
(by a mean difference of 23.03 hours; 95% confidence 
interval, 0.45-45.61 hours) than that with heparin.18 
The main reason for the discrepancy between the 
findings by Zhang and Hongying18 (which showed 
more favourable circuit life for citrate group vs 
heparin group) and Wu et al19 (which showed 
comparable circuit life between citrate and heparin 
groups) was attributed to the study by Betjes et al,17 
which did not report interquartile ranges of circuit 
survival. While Zhang and Hongying18 estimated the 
survival time in this study by Kaplan-Meier analysis, 
Wu et al19 excluded it from their circuit survival 
analysis. With the improved circuit life, citrate can 
decrease circuit downtime and minimise discrepancy 
between prescribed and delivered CRRT dose, 
achieve lower treatment cost, avoid unnecessary 
blood loss, and reduce nursing workload. In fact, the 
latest Kidney Disease Improving Global Outcomes 
Clinical Practice Guidelines recommended citrate 
as the anticoagulant of choice in patients requiring 
CRRT.21 
Metabolic control
Concerning reversal of metabolic acidosis and 
control of uraemia, most RCTs12,13,17 reported similar 
efficacy when comparing citrate- with heparin-
based CRRT, except one study16 which was in favour 
of citrate. This might be explained by the longer 
circuit lifetime, which offered better uraemic toxin 
clearance.
Bleeding events
All RCTs,12,13,15-17 except one,14 showed a higher 
bleeding risk with heparin-based CRRT when 
compared with citrate anticoagulation (Table 1). 
All the three meta-analyses18-20 demonstrated a 
significantly lower incidence of bleeding in citrate-
based CRRT compared with heparin, with a pooled 
risk ratio ranging from 0.25 to 0.34. However, 
the definition of bleeding events varied in all the 
included trials. Blood transfusion requirement was 
lower in the citrate group when compared with the 
unfractionated heparin group.20 
Mortality
Three studies provided outcome information on 
mortality (Table 1).12,13,15 The study by Kutsogiannis 
et al15 was relatively small (n=30, mortality rate of 
citrate group vs heparin group = 81% vs 71%; P=0.69) 
and was not powered to detect survival difference.
The single-centre study by Oudemans-van Straaten 
et al13 showed a mortality benefit at 3 months (48% 
FIG 1.  Citrate-based continuous venovenous haemodialysis
4% Sodium citrate solution
Blood flow: 130 mL/min
Ci-Ca Dialysate K2 solution 
at 2600 mL/h
10% CaCl2 solution
High-flux haemofilter
Effluent
FIG 2.  Citrate-based continuous venovenous haemodiafiltration
FIG 3.  Citrate-based continuous venovenous haemofiltration
Prismocitrate 10/2 
solution at 2500 mL/h
Blood flow: 150 mL/min
8.4% Sodium bicarbonate 
solution at 30 mL/h
10% CaCl2 solution
High-flux haemofilter
Effluent
Prismocitrate 18/0 solution 
at 1500 mL/h
Blood flow: 150 mL/min
Prismo0cal B22 dialysate 
solution at 1500 mL/h
10% CaCl2 solution
High-flux haemofilter
Effluent
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vs 63% respectively; P=0.03) when comparing citrate 
with low-molecular-weight heparin. Mortality was 
mainly reduced in surgical patients, those with 
sepsis, those younger (<73 years), and in patients 
with higher Sepsis-related Organ Failure Assessment 
scores (>11 points). The study speculated that 
citrate, apart from being an excellent anticoagulant 
for CRRT, might have immunomodulatory actions 
that suppress inflammation, thus, leading to a 
survival benefit in critically ill patients.13 However, 
a subsequent multicentre study by Hetzel et al12 
failed to demonstrate such benefit. While Hetzel 
et al12 used unfractionated heparin, Oudemans-van 
Straaten et al13 used a low-molecular-weight heparin 
preparation. Hetzel et al12 also included subjects 
who were younger and more septic. The discrepancy 
in clinical background and the different mode of 
anticoagulation might explain the difference in the 
observed results. It was important to note that both 
studies were not sufficiently powered to ascertain 
survival benefit of regional citrate anticoagulation, 
and mortality rate was not the primary end-point. A 
properly powered, well-designed RCT is required to 
clarify this issue. 
Side-effects
Citrate anticoagulation has complex metabolic 
consequences due to its physiochemical property. 
Apart from being an anticoagulant, it also serves as 
a pH buffer, chelating agent, and a source of energy 
and sodium. 
Citrate toxicity
A recent pharmacokinetic study showed that citrate 
clearance is not impaired in critically ill patients.22 
However, reduced metabolism of citrate occurs 
in patients with chronic liver disease, ischaemic 
hepatitis, hypoxia and impaired muscle perfusion, 
which are commonly found in the ICU setting. Citrate 
accumulation results in ionised hypocalcaemia and 
acidosis, which cause hypotension due to decreased 
myocardial contractility and vascular hypotonia. A 
paradoxical increase in total calcium concentration 
often occurs due to increased citrate-bound calcium, 
as well as the increased use of calcium replacement 
in response to ionised hypocalcaemia. The total-
to-ionised calcium ratio is, therefore, an important 
marker to detect citrate accumulation.23,24 An 
TABLE 1.  Characteristics and major findings of randomised controlled trials comparing regional citrate- and heparin-based continuous renal 
replacement therapy12-17
Hetzel et al12 Oudemans-van 
Straaten et al13
Fealy et al14 Betjes et al17 Kutsogiannis 
et al15
Monchi et al16
Year of publication 2011 2009 2007 2007 2005 2004
Centre Multi Single Single Single Multi Single
No. of patients C: 87
H: 83
C: 97
H: 103
C: 10
H: 10
C: 21
H: 27
C: 16
H: 14
C: 8
H: 12
Age (years) C: 62*
H: 65*
C: 73†
H: 73†
C & H: 71† C: 58*
H: 55*
C: 67*
H: 64*
C: 67†
H: 64†
Sepsis C: 77%
H: 74%
C: 43%
H: 49%
C & H: 30% C: 76%
H: 59%
C: 31%
H: 43%
C: 50%
H: 42%
Treatment Citrate vs UFH Citrate vs LMWH Citrate vs regional UFH Citrate vs UFH Citrate vs UFH Citrate vs UFH
Circuit lifespan (hours) C: 38
H: 26
C: 27
H: 26
C: 17
H: 13
C: 36
H: 38
C: 124
H: 38
C: 70
H: 40
Control of acidosis Similar Similar NR Similar NR Similar 
Control of uraemia Similar Similar NR Similar NR In favour of citrate
Mortality C: 47%
H: 41% 
C: 42%
H: 57%
NR NR C: 81%
H: 71%
NR
Renal recovery NR C: 69%
H: 52%
NR NR NR NR
Bleeding events C: 6%
H: 15%
C: 6%
H: 16%
C: 0%
H: 0%
C: 0%
H: 33%
C: 6%
H: 57%
C: 0%
H: 8%
Metabolic alkalosis Similar C: 9%
H: 19%
NR C: 0%
H: 7%
C: 6%
H: 0%
C: 13%
H: 0%
Hypocalcaemia C: 1%
H: 0%
C: 6%
H: 2%
NR C: 9%
H: 0%
C: 6%
H: 0%
C: 13%
H: 0%
Abbreviations: C = regional citrate group; H = heparin group; LMWH = low-molecular-weight heparin; NR = not reported; UFH = unfractionated heparin
* Mean age
† Median age
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elevated ratio of >2.25 should alert the clinician to 
the possibility of citrate accumulation. Impaired 
citrate metabolism is an independent risk factor for 
mortality. A ratio of ≥2.4 independently predicted 
a 33.5-fold increase in 28-day mortality rate in 
critically ill patients.25 There was also a significant 
correlation between total-to-ionised calcium ratio 
and the severity of critical illness. Citrate toxicity 
should be suspected, based on the presence of the 
following three observations, namely, elevated 
total-to-ionised calcium ratio of >2.25, increased 
use of calcium replacement, and increasing 
metabolic acidosis. Clinically, patients may present 
with symptoms of hypocalcaemia like circumoral 
paraesthesia, carpopedal spasm, generalised tetany, 
and hyper-reflexia.26 Prolonged QT interval may 
follow by the development of Torsades de pointes 
or ventricular arrhythmia in untreated patients.26 
Confirmation of citrate intoxication can only be 
done by checking citrate concentration in blood, 
which is not readily available in most hospital 
laboratories. Therefore, clinical symptoms and signs 
are suggestive but not diagnostic of citrate toxicity. 
In highly suspicious cases, citrate infusion should 
be stopped immediately, followed by intravenous 
calcium injection. Continuous renal replacement 
therapy could be resumed using citrate-free regimen 
after initial stabilisation. Despite the potential risks 
associated with citrate toxicity, CRRT with citrate 
anticoagulation is considered feasible in patients with 
liver impairment,27 provided that careful monitoring 
of calcium level and meticulous titration are ensured. 
Citrate accumulation should be minimised with the 
reduction in citrate infusion, increase in effluent 
flow to promote citrate clearance, adequate calcium 
replacement to counteract hypocalcaemia, and 
supplementation with extra bicarbonate to correct 
acidosis. 
Metabolic derangement
Recent meta-analyses showed no significant 
difference in the incidence of metabolic alkalosis 
in citrate groups compared with heparin 
groups in patients with normal metabolism.19,20 
Hypernatraemia is a problem commonly associated 
with the use of concentrated citrate solution (4% 
trisodium citrate solution has 544 mmol/L sodium 
while Anticoagulant Citrate Dextrose Solution A 
[ACDA] has 224 mmol/L sodium). Adoption of a 
slightly hyponatraemic replacement or dialysate 
solution in the CRRT regimen may be a remedy to 
this problem. Alternatively, normonatraemic citrate 
solution may be used, for instance, Prismocitrate 18/0 
or Prismocitrate 10/2 (Gambro Hospal, Stockholm, 
Sweden), which serves as both an anticoagulant and 
a source of buffer for predilutional treatment.28,29 The 
drawback of this method is that it does not guarantee 
a fixed relationship between citrate and blood flow. 
This is due to the fact that the amount of replacement 
fluid entering the circuit is dependent on filtrate 
flow and the desired amount of fluid removal, 
which are prone to variations. The varying citrate 
concentration may consequently exert a negative 
effect on the circuit survival time. This issue can 
be resolved by fixing the flow ratio between blood 
and the citrate-containing substitution fluid. Citrate 
binds to magnesium, resulting in excessive loss in 
filtrate and causing hypomagnesaemia, which in 
turn decreases the release of parathyroid hormone, 
promotes hypokalaemia, and induces tetany as well 
as cardiac arrhythmia. Monitoring and replacement 
of magnesium should be done regularly. 
Energy gain
Citrate also serves as a source of energy with 0.59 
kcal/mmoL and can enter cells without insulin. The 
bioenergetic gain of citrate-anticoagulated CRRT is 
not limited to citrate itself, but is also contributed 
by glucose (in ACDA) and lactate (in replacement 
or dialysate solution). The energy delivered can 
differ substantially between modalities, even with 
comparable doses.30 Such information should, 
therefore, be taken into account when nutritional 
needs are being calculated.
Treatment cost
The composition of commonly used fluid for CRRT 
is shown in Table 2. Using average filter life (citrate 
vs heparin = 52 hours vs 30 hours) calculated based 
on previously published RCTs (Table 1), the total 
treatment cost for citrate-based CRRT lasting for 
72 hours is around HK$10 000 (using continuous 
venovenous haemodiafiltration with 1250 mL/h pre-
filter citrate containing replacement solution plus 
1250 mL/h dialysate flow rate and two haemofilter/
circuit changes within 72 hours of treatment). The 
cost is similar to that of heparin-based regimen 
(using continuous venovenous haemodiafiltration 
with 1250 mL/h post-filter replacement solution plus 
1250 mL/h dialysate flow rate and three haemofilter/
circuit changes within 72 hours of treatment). 
Future development
Development of fluid for citrate-based 
continuous renal replacement therapy
The setup of regional citrate anticoagulant with 
conventional CRRT machines was more complicated 
compared with other anticoagulants. Since 1995, 
citrate in the form of ACDA had been the default 
anticoagulation method for CRRT in our unit, as 
described by Leung and Yan.31 The solutions for 
replacement are customised (with low bicarbonate 
and sodium level) as a concentrated citrate solution 
will provide extra sodium and bicarbonate load. 
Reconstitution of this customised replacement fluid 
#  Citrate for continuous renal replacement therapy  # 
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was tedious, time-consuming, and error-prone. The 
next evolution was to use online replacement fluid 
generated from Gambro AK200 Ultra S (Gambro 
Hospal, Stockholm, Sweden) together with post-
dilution continuous venovenous haemofiltration 
with citrate anticoagulation using ACDA. The 
advantage of this system was the flexibility of 
adjusting sodium and bicarbonate concentrations 
with the replacement solution generated online. It 
also came at a lower treatment cost due to generation 
of sterile replacement fluid via the online system.32 
However, generation of ultra-pure water is a pre-
requisite for implementation, and ICUs without 
pre-installed water delivery and treatment systems 
will be precluded from this treatment technology. In 
the recent 10 years, commercially prepared citrate-
containing replacement solution and tailor-made 
dialysate have become widely available (Table 2), 
and citrate-based CRRT has been widely adopted in 
different ICUs. 
Machine and protocol development
Previous CRRT machines were not specifically 
designed for citrate-based treatment. Additional 
infusion pumps for continuous citrate administration 
were required during treatment, and posed major 
safety problems. When the CRRT machine alarm 
sounds for bag exchange or for other mechanical 
problems, all CRRT infusion pumps will stop 
except for the pump used to infuse the citrate 
solution, which may result in the direct infusion 
of citrate solution into the patient. Nowadays, the 
new CRRT machines have incorporated integrated 
citrate modules and specific protocols. Continuous 
monitoring of citrate and ionised calcium levels 
together with computerised algorithms may further 
improve patient safety and minimise potential side-
effects.33,34 Yet, successful implementation of the 
protocol requires focused and continuous training 
for the involved clinical staff. 
Conclusion
Citrate is a safe and effective anticoagulant for 
CRRT. Its advantages can be fully appreciated with 
a simple, well-devised and practicable protocol, and 
appropriate clinical staff training.
Abbreviations:  ACDA = Acid Citrate Dextrose Solution A; ACDB = Acid Citrate Dextrose Solution B; Ca = calcium; Cl = chloride; FMC = Fresenius 
Medical Care; Mg = magnesium; Na = sodium; K = potassium
TABLE 2.  Composition of fluids available in Hong Kong for continuous renal replacement therapy
Na 
(mmol/
L)
K 
(mmol/
L)
Ca 
(mmol/
L)
Mg 
(mmol/
L)
Cl 
(mmol/L)
Lactate 
(mmol/L)
Acetate 
(mmol/
L)
Bicar-
bonate 
(mmol/
L)
Citrate 
(mmol/
L)
Citric 
acid 
(mmol/
L)
Glucose 
(g/L)
HPO42- 
(mmol/L)
Osmol-
arity 
(mOsm/L)
FMC multiBic (free K+) 140 0 1.5 0.5 109 0 0 35 0 0 1 0 290
FMC multiBic (K+ 2) 140 2 1.5 0.5 111 0 0 35 0 0 1 0 294
FMC multiBic (K+ 3) 140 3 1.5 0.5 112 0 0 35 0 0 1 0 296
FMC multiBic (K+ 4) 140 4 1.5 0.5 113 0 0 35 0 0 1 0 298
FMC multiPlus (K+ 2) 140 2 1.5 0.75 109.7 0 0 35 0 0 1 1 295
FMC Ci-Ca Dialysate K2 133 2 0 0.75 116.5 0 0 20 0 0 1 0 278
FMC Ci-Ca Dialysate K4 133 4 0 0.75 118.5 0 0 20 0 0 1 0 282
FMC Ci-Ca Dialysate K2 Plus 133 2 0 1 115.75 0 0 20 0 0 1 1.25 278
FMC Ci-Ca Dialysate K4 Plus 133 4 0 1 117.75 0 0 20 0 0 1 1.25 282
Gambro Hemosol BO 140 0 1.75 0.5 109.5 3 0 32 0 0 0 0 287
Gambro Prism0cal 140 0 0 0.5 106 3 0 32 0 0 0 0 282
Gambro Prism0cal B22 140 4 0 0.75 120.5 3 0 22 0 0 6.1 0 296
Gambro Phoxilium 140 4 1.25 0.6 115.9 0 0 30 0 0 0 1.2 293
Haemofiltration solution 1 140 1 1.62 0.75 100.75 45 0 0 0 0 2 0 300
Haemofiltration solution 2 135 2 1.87 0.75 108.5 33.75 0 0 0 0 1.5 0 290
Haemofiltration solution 3 135 0 1.87 0.75 106.5 33.75 0 0 0 0 1.5 0 286
Haemofiltration solution 4 135 3 1.87 0.75 109.5 33.75 0 0 0 0 1.5 0 292
Haemofiltration solution 5 140 0 2 1 111 0 35 0 0 0 1.5 0 292
ACDA 225 0 0 0 0 0 0 0 75 38 22.3 0 462
ACDB 135 0 0 0 0 0 0 0 45 23 13.4 0 277
FMC Trisodium citrate 4% 408 0 0 0 0 0 0 0 136 0 0 0 544
Gambro Prismocitrate 10/2 136 0 0 0 106 0 0 0 10 2 0 0 254
Gambro Prismocitrate 18/0 140 0 0 0 86 0 0 0 18 0 0 0 244
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